These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19545555)

  • 1. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping.
    Babic N; Haverfield EV; Burrus JA; Lozada A; Das S; Yeo KT
    Clin Chim Acta; 2009 Aug; 406(1-2):143-7. PubMed ID: 19545555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
    King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
    Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
    Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
    Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.
    Langley MR; Booker JK; Evans JP; McLeod HL; Weck KE
    J Mol Diagn; 2009 May; 11(3):216-25. PubMed ID: 19324988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
    Maurice CB; Barua PK; Simses D; Smith P; Howe JG; Stack G
    Clin Chim Acta; 2010 Jul; 411(13-14):947-54. PubMed ID: 20226775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population.
    Efrati E; Elkin H; Sprecher E; Krivoy N
    Curr Drug Saf; 2010 Jul; 5(3):190-3. PubMed ID: 20210733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
    Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes.
    Howard R; Leathart JB; French DJ; Krishan E; Kohnke H; Wadelius M; van Schie R; Verhoef T; Maitland-van der Zee AH; Daly AK; Barallon R
    Clin Chim Acta; 2011 Nov; 412(23-24):2063-9. PubMed ID: 21827742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.
    Li Y; Jortani SA; Ramey-Hartung B; Hudson E; Lemieux B; Kong H
    Clin Chim Acta; 2011 Jan; 412(1-2):79-85. PubMed ID: 20854800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated amplification microarray system in a lateral flow cell for warfarin genotyping from saliva.
    Sebastian T; Cooney CG; Parker J; Qu P; Perov A; Golova JB; Pozza L; Iwasiow RM; Holmberg R
    Clin Chim Acta; 2014 Feb; 429():198-205. PubMed ID: 24360850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Warfarin resistance and related pharmacogenetic information].
    Takahashi H
    Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels.
    Lee CC; McMillin GA; Babic N; Melis R; Yeo KT
    Clin Chim Acta; 2011 May; 412(11-12):1133-7. PubMed ID: 21385571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.
    Rettie AE; Farin FM; Beri NG; Srinouanprachanh SL; Rieder MJ; Thijssen HH
    Br J Clin Pharmacol; 2006 Nov; 62(5):617-20. PubMed ID: 16869821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.